Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $60.00 and last traded at $57.35, with a volume of 337658 shares changing hands. The stock had previously closed at $59.46.
Gemini Therapeutics Stock Down 3.5 %
The business has a fifty day moving average of $50.98 and a 200 day moving average of $44.90. The firm has a market cap of $2.48 billion, a P/E ratio of -59.46 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- How to invest in marijuana stocks in 7 steps
- Applied Materials Market Capitulates: Now is the Time to Buy
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
